Publications

PALI-2108 Phase 1b Clinical Data View PDF

PALI-2108, A Colon-Specific PDE4 Inhibitor Prodrug, is Bioactivated in the Colon and Reduces Colon Tissue PDE4B in a Dose-Dependent Manner, Increasing c-AMP and Suppressing TNF-α in A Mouse Model of Colitis View PDF

A Bioinformatic Approach to PALI-2108 Treatment in Ulcerative Colitis Reveals the Potential for Anti-Fibrotic Efficacy with Local PDE4 Inhibition in Intestinal Fibrosis View PDF

PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug, Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model View PDF

Detailing Characteristics of Fibrostenotic Crohn’s Disease Biology & the Potential of a Local PDE4 Inhibitor Prodrug to Minimize Off-Target Effects & Maximize Efficacy View PDF

Colonic Bioactivation and Potent TNFa Inhibition of PALI-2108 in Human Clinical Studies: A Promising PDE4 Inhibitor Prodrug for the Oral Treatment of Ulcerative Colitis View PDF

Local Bioactivation and Efficacy of PALI-2108: A Promising PDE4 Inhibitor Prodrug for Ulcerative Colitis Treatment View PDF